Genmab — April 2018

[rex_pacis]

God formiddag fra Amager

[Bulder]

Så er spørgsmålet om det vil give ekstra at tilføje dara http://onkologisktidsskrift.dk/behandlinger/lungekraeft/758-nsclc-patienter-overlever-med-lungekraeft-efter-tecentriq-behandling.html

[Bulder]

Keytruda klarer sig også fint i nsclc. http://onkologisktidsskrift.dk/behandlinger/lungekraeft/763-peter-meldgaard-keytruda-kombination-oger-overlevelsen-markant-for-nsclc.html

[Bulder]

Der kører ikke kombiforsøg med dara-pembro i nsclc. Kun i RRMM og et blandet i NHL.

[E_L]

Onclive article : Novel Approaches Emerge in AL Amyloidosis
https://www.onclive.com/web-exclusives/novel-approaches-emerge-in-al-amyloidosis

[E_L]

Daratumumab (HuMax-CD38) Safety Study in Multiple Myeloma - https://clinicaltrials.gov/ct2/show/study/NCT00574288?term=daratumumab+OR+ofatumumab+OR+tisotumab&lupd_s=04%2F27%2F2018&rank=1&sect=X01256 - results posted

[E_L]

we have seen these before; it is GEN501

[E_L]

most of these hospitals finished
recruiting now on this (D-RVd) trial, some even complete https://clinicaltrials.gov/ct2/show/study/NCT02874742?term=daratumumab+OR+ofatumumab+OR+tisotumab&lupd_s=04%2F27%2F2018&rank=2&show_locs=Y#locn

[E_L]

Treatment With Bendamustine, Ofatumumab and MethylPrednisolone in Relapsed B-CLL (BOMP) was Terminated https://clinicaltrials.gov/ct2/show/NCT01612988?term=daratumumab+OR+ofatumumab+OR+tisotumab&lupd_s=04%2F27%2F2018&rank=4
(which makes sense, it wasnt even a Novartis study)

[E_L]

Onclive video : Dr. Voorhees on Treatments for Patients With Relapsed Multiple Myeloma

• https://www.onclive.com/onclive-tv/dr-voorhees-on-treatments-for-patients-with-relapsed-multiple-myeloma

[Bulder]

Very uplifting E L. They have also changed the primary completion date for the Griffin study from nov. 4. 2019 to dec. 31. 2018! A whole year. I wouldn't be surprised if they chose to file on that study. Even though it's only a phase 2. That would mean filing on the last frontline segment already next year.

[Bulder]

We already have Alcyone. Maia and Cassiopeia will com soon. The only left is Griffin. Then the whole fronline settting is covered.

[Bulder]

Maybe it is a little early to expect a filing on the basis of Griffin. In November Winkel said: "Janssen is currently planning a Phase 3 study in D-RVd, and the Phase 2 data if
positive could be included in a compendium listing."

[GeorgeBest]

E L & Bulder. So are so diligent, even in the weekends. Thanks a lot. We all profit from it....

[GeorgeBest]

You are so diligent,..

[bikube]

Seeking Alfa - Under Stocks To Watch - Upcoming stoch splits: Genmab (OTCPK:GMXAY) 5-for-1.

[peter12]

Det lyder mærkeligt ? https://seekingalpha.com/article/4167213-stocks-watch-apple-fomc-china-tap?page=2

[pauly]

Mange har jo ønsket et split, men det er da nyt. Gu´ved om det også kommer til den danske notering hvis det altså passer

[peter12]

Mon ikke det er en and ? Så skal JDW da have skiftet mening. Måske nogle store investorer kan presse dem.

[bikube]

Jeg kan ikke få øje på, hvorfor man skulle lave split i U S. Kursen derovre er $103. Der har jo længe været nogle, der har ønsket et split, men JvDW har jo hidtil afvist, at der skulle være planer derom. Det kan da være, at han læser med, og dementerer eller bekræfter rygtet.